| 摘要 |
Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4&bgr;7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4&bgr;7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4&bgr;7 antibody in vivo. |
